Moreover, additional studies are required to determine whether NaCT inhibition acts synergistically with other drugs that are currently in clinical development for NASH, such as GLP1, thyroid hormone receptor (THR) β, farnesoid X receptor (FXR), or PPAR agonists. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.